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396 T. Hirama et al.Commensal organism;
Foreign organismrapid, accurate, easily performed, and cost-effective. Here, we devised a PCR-based test,
named HIRA-TAN, which is able to discriminate therapeutic targets from commensal organisms
(e.g. Streptococcus pneumoniae or Haemophilus influenzae) and to detect foreign organisms
(e.g. Mycoplasma pneumoniae or Legionella pneumophila) in the sputum. The utility of this
system was validated in a prospective study, using sputum samples from patients with pneu-
monia. 568 patients were enrolled and the HIRA-TAN assay identified the causative pathogens
with an accuracy of 96.7% for H. influenzae; 93.2% for Pseudomonas aeruginosa; 80.6% for
Klebsiella pneumoniae; 90.9% for Moraxella catarrhalis; 87.5% for Escherichia coli; 78.1% for
MRSA and 91.6% for S. pneumoniae. Overall the HIRA-TAN procedure was able to identify
the causative pathogens of pneumonia in 60% of the cases. Additionally, this procedure was
able to determine when the pneumonia-causing organism was a commensal organism or a
foreign organism in a single assay. The HIRA-TAN approach yielded reproducible results and
provided valuable information to plan the course of treatment of pneumonia. Through the
rapid identification of the causative pathogens, the HIRA-TAN will promote targeted treat-
ments for pneumonias. Clinical Trials Registration: UMIN000001694.
ª 2013 The Authors. Published by Elsevier Ltd.Open access under CC BY-NC-ND license.Introduction
Pneumonia is a significant cause of morbidity and mortality
in clinical settings. Clinical tests involving smear and cul-
ture of sputum, antigen tests, and paired antibody titers
often fail to identify the causative pathogen(s) of pneu-
monia. The rapid identification of the causative patho-
gen(s) would allow for the selection of targeted antibiotics.
Accordingly, timely identification has been shown to
reduce the mortality rate and the emergence of drug-
resistant pathogens [1,2]. To identify such pathogens and
thus obtain the desired benefits, a clinical test is required
that is rapid, accurate, easily performed, and cost-
effective.
In a previous study, we proposed the “battlefield hy-
pothesis”, which postulated that the organism-to-human
cell number ratio may be an index for the pathogenic role
of the organism [3]. The ratio was determined using a real-
time PCR-based approach and used to evaluate a major
commensal organism, Streptococcus pneumoniae (S.
pneumoniae), with the results supporting our battlefield
hypothesis. We devised a PCR-based test of sputum samples
that can differentiate pathogens that are the likely causa-
tive pathogens of pneumonia from commensal organisms.
Combining the described PCR system for commensal or-
ganisms with PCR detection system for foreign organisms
constitute the HIRA-TAN (human cell-controlled identifica-
tion of the respiratory agent from “TAN”, which means
sputum in Japanese) (Table 1).
Currently PCR-based approaches are mainly used to
identify foreign organisms in respiratory specimens [4e6].
Even if such clinical tests have a multiplex detection
system, identification of foreign organisms alone shows
limited clinical value. In the current study, we have
expanded the scope and utility of this approach by opti-
mizing newly developed primers and cutoff values. We
also focused on the detection of additional target or-
ganisms with a larger number of patient samples and
broader coverage of the relevant microorganisms. We
describe the ability of the procedure to identifycommensal organisms and the overall performance of the
HIRA-TAN system.
Materials and methods
Patients
Patients were eligible if they met the following criteria: (1)
Clinical symptoms suggestive of pneumonia: cough, fever
(>38.5 C), sputum production, chest discomfort/pain, or
dyspnea. (2) Newly developed pulmonary infiltrates in
chest radiological examination. A diagnosis of pneumonia
was clinically made when patients presented with both (1)
and (2) without an alternative cause [7e12]. (3) Gram stain
and culture of expectorated sputum submitted before the
treatment. (4) Urine antigen (UA) test for S. pneumoniae
submitted. (5) Age 18 years or older. (6) Written informed
consent obtained. And for the additional analysis, blood
sample for bacterial culture (admitted case only), UA test
for Legionella pneumophila (admitted case only) and
Influenza antigen test (flu season only) were also submitted
when possible. Patient enrollment was performed from May
2007 to January 2009 (the past clinical study) and from
February 06, 2009 to October 14, 2010 (the prospective
study) at the Saitama Medical University Hospital and the
participating institutes (Table 2).
Samples
Sputum, inducedsputum,or sputumobtainedbyintra-tracheal
aspiration (sputumhereafter)wascollected frompatientswith
pneumonia. Samplesweremixedwellbypipetting,anddivided
into 2; one was submitted for a bacteriological test, and the
other was submitted for HIRA-TAN based analysis. To select
purulent sputum, samples with M2eP3 appearance aswell as a
Cthuman<27 (thehuman-specific genewithCt (threshold cycle)
value by the real-time PCR) were studied [3]. Classification of
the gross appearance of the sputum (M1, M2, P1, P2, and P3)
was according to Miller and Jones.
Table 1 List of targets, genes and its affiliation (CO, NCO or DRRG) in the HIRA-TAN.
Targeta Gene DCt cutoff value
1 Homo sapiens SFTPC
2 Streptococcus pneumoniae lytA CO 6
3 Haemophilus influenzae 16S rRNA CO 1
4 Moraxella catarrhalis copB CO 0
5 Pseudomonas aeruginosa 23S rRNA CO 4
6 Klebsiella pneumoniaeb gapA CO 6
7 Escherichia coli phoA CO 7
8 Staphylococcus aureus femB CO 7
9 Mycoplasma pneumoniae 16S rRNA NCO
10 Chlamydophila pneumoniae 53KD-antigen NCO
11 Chlamydophila psittaci ompA NCO
12 Coxiella burnetii transposase NCO
13 Legionella spp. 16S rRNA NCO
14 Legionella pneumophila mip NCO
15 Bordetella pertussis BP485 NCO
16 Mycobacterium Tuberculosis MPB64 NCO
17 Mycobacterium intracellulare ITS 16-23S rRNA NCO
18 Mycobacterium avium 16S rRNA NCO
19 Mycobacterium kansasii dnaJ NCO
20 Pneumocystis jirovecic 5S rRNA NCO
21 Nocardia spp. 16S rRNA NCO
22 Metallo-beta-lactamasee IMP DRRG
23 Methicillin-resistant S. aureusd mecA DRRG 8
a H. sapiens, Homo sapiens; S. pneumoniae, Streptococcus pneumoniae; H. influenzae, Haemophilus influenzae; M. catarrhalis,
Moraxella catarrhalis; P. aeruginosa, Pseudomonas aeruginosa; K. pneumoniae, Klebsiella pneumonia; E. coli, Escherichia coli; MSSA,
Methicillin-sensitive Staphylococcus aureus; MRSA, Methicillin-resistant Staphylococcus aureus; M. pneumoniae, Mycoplasma pneumo-
niae; C. pneumoniae, Chlamydophila pneumoniae; C. psittaci, Chlamydophila psittaci; C. burnetii, Coxiella burnetii; L. pneumophila,
Legionella pneumophila; B. pertussis, Bordetella pertussis; M. tuberculosis, Mycobacterium tuberculosis; M. intracellulare, Mycobac-
terium intracellulare; M. avium, Mycobacterium avium; M. kansasii, Mycobacterium kansasii; P. jiroveci, Pneumocystis jiroveci; CO,
commensal organism; NCO, non-commensal organism (foreign organism); DRRG, drug-resistant-related gene.
b The PCR reaction for K. pneumoniae only has need of starting at 95 C for 30 s followed by 40 cycles of 95 C for 10 s, 61 C for 35 s,
and 72 C for 25 s.
c Since Pneumocystis jiroveci was not normally identified from the healthy individuals, it was classed together as foreign organism.
d Methicillin-resistant Staphylococcus aureus (MRSA) was judged as therapeutic target in HIRA-TAN both when S. aureus (femB gene)
was detected above 7 in the DCtS. aureus cutoff and when DRRG (mecA gene) was also detected above 8 in the DCtMRSA cutoff
altogether.
e 5 IMP producing P. aeruginosa was judged as therapeutic target in HIRA-TAN both when P. aeruginosa was detected above 6 in the
DCtP. aeruginosa cutoff and IMP gene was detected altogether.
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The sputum was diluted with an equal volume of
phosphate-buffered saline and homogenized by vortexing.
A portion of the homogenate (200 mL) was taken and mixed
with AL buffer (200 mL; Qiagen, Tokyo, Japan) containing
>12 mAU of proteinase K, and the resultant mixture was
incubated at 56 C for 1 h. DNA was isolated into 100 mL of
TE buffer with the QIAamp DNA Blood Mini Kit (Qiagen).
Pathogens
Commensal organism
Commensal organisms form part of human normal flora in the
respiratory system. However, in specific situations as when
the host defense is weakened, the number of organisms
grows beyond their typical ranges, and then pneumonia oc-
curs. Commensal organisms cause more than half ofpneumonias. Since the majority of them reside in the respi-
ratory tract, when they are detected from respiratory sam-
ple, there is no unequivocal criterion to discriminate
causative pathogen from colonizing one by the sputum ex-
amination (e.g., S. pneumoniae,Haemophilus influenzae (H.
influenzae) or Pseudomonas aeruginosa (P. aeruginosa)).
Foreign organism (non-commensal organism)
Foreign organisms are the cause of less than half of pneu-
monias. They do not reside in the respiratory tract of healthy
individuals, and thus their detection indicates that they are
the causative pathogens (e.g., Mycoplasma pneumoniae, L.
pneumophila or Mycobacterium tuberculosis).
Criteria for commensal organisms to be the likely
causative pathogen
A commensal organism that fulfilled at least 1 of the
following 3 criteria was considered to be a likely
Table 2 The Protocol synopsis for the prospective study.
Title A multicenter prospective study for the investigation of the validity of the cutoff values
established for the HIRA-TAN system.
Study design This is a multi-centre, observational study
Study period and sample size Between Feb 06, 2009 and Feb 05, 2011. This study will be terminated before Feb 05, 2011;
when the total number of patients reaches 600, or when the number of patients with
pneumonia in which both H. influenzae and P. aeruginosa are the likely causative pathogen
reaches 30 each.
Number of sites Seven institutions, nine departments, altogether -Saitama Medical University (http://www.
saitama-med.ac.jp) -Department of respiratory medicine -Department of General Internal
Medicine -Saitama Medical University International Medical Center (http://www.saitama-
med.ac.jp/kokusai/) -Department of Respiratory Medicine -Department of Emergency and
Acute Medicine -Kan-etsu Hospital (http://www.kan-etsu-hp.ne.jp/hospital/) -Saitama
Social Insurance Hospital (http://www1.biz.biglobe.ne.jp/wsaitahp/top.html)
-Tsurugashima Ikenodai Hospital (http://www.ikenodai.com) -Kesennuma City Hospital
(http://www.kesennuma-hospital.jp) -Ohno clinic (http://www.ohno-clinic.or.jp/access/
index.html)
Primary endopoint The proportion of the samples in which H. influenzae and P. aeruginosa are judged as
therapeutic targets to those in each are shown to be likely causative pathogens
Secondary endopoint The proportion of the samples in which K. pneumoniae, M. catarrhalis, E. coli, S. aureus and
S. pneumoniae are judged as therapeutic targets to those in each are shown to be likely
causative pathogens The proportion of the samples in which the HIRA-TAN identified the
therapeutic target (commensal organisms judged by the DCt cutoff) and the causative
pathogen (foreign organisms detected by the real-time PCR)
Subject selection criteria Inclusion Criteria: Patients were eligible if they met the following criteria: (1) Clinical
symptoms suggestive of pneumonia: cough, fever (>38.5 C), sputum production, chest
discomfort/pain, or dyspnea. (2) Newly developed pulmonary infiltrates in chest
radiological examination. (3) Gram stain and culture of expectorated sputum submitted
before the treatment. (4) Urine antigen test for S. pneumoniae. (5) Age 18 years or older.
(6) Written informed consent obtained. And for the additional analysis, blood sample for
bacterial culture (admitted case only), Urine antigen test for L. pneumophila (admitted
case only) and Influenza antigen test (flu season only) were also submitted as possible.
Exclusion Criteria: Patients did not fulfill the criteria (1)e(6).
Funding organization This work is supported in part by a Grant-in-Aid for Young Scientists (B) (No. 21790784) from
the Japan Society for the Promotion of Science, in part by the Saitama Medical University
Internal Grant 09-01 (No. 21-2-2-06) from Saitama Medical University, in part by the Grant-
in-Aid from Ochiai Memorial Foundation and in part by a Grant-in-Aid for Young Scientists
(B) (No. 23790918) from the Japan Society for the Promotion of Science. No additional
external funding received for this study.
Registration number The study had been registered to the University Hospital Medical Information Network
(UMIN) registry before its initiation (UMIN000001694) and approved by the Saitama Medical
University Hospital IRB committee (08-063)
398 T. Hirama et al.causative pathogen when: (1) an organism was identified
from the normally sterile site (blood or pleural effusion);
(2) a morphologically compatible organism, coexisting
with abundant neutrophils, was observed through
Gram staining later confirmed by sputum culture; or (3)
for S. pneumoniae only: the urine antigen test was po-
sitive.
Criteria for foreign organisms to be the causative
pathogen
Foreign organisms that fulfilled at least 1 of the following
2 criteria was considered to be a causative pathogen
when: (1) an organism was identified by culture, antigen
test (involving serum, urine or nasopharyngeal specimen)
or PCR test; or (2) paired serological test revealed a
significant increase in antibody titer (more than four
times).Criteria for commensal organisms to be the therapeutic
target by HIRA-TAN
We developed the HIRA-TAN: a real-time PCR-based test
for sputum that was established in simultaneous multi-
pathogen detection as previously described [3]. The cutoff
value was determined for each commensal organism,
which enabled us to discriminate the bona fide thera-
peutic target from other commensal organisms detected
by real-time PCR. With the assumption being that the high
relative levels of any of the given candidate pathogens
would increase its likelihood of being the causative path-
ogen. Here we expanded the number of PCR reactions to
23 with organism specific target genes for quantifying 7
commensal organisms, 13 foreign organisms, 2 drug
resistance-related genes (DRRG), and the human-specific
gene (as internal control) in the HIRA-TAN (Table 1).
Compared with our previous study here we used newly
Identification of causative agents of pneumonia 399designed primer pairs and cutoff value for each target
(Suppl Table 1).
Real-time PCR reaction
A database search was used to select potential DNA se-
quences to identify microorganisms of interest. The primers
and probes were validated using genomic DNA from the
microorganism of interest as well as screened against 74
other microorganisms (Suppl Table 1). The final solution of
PCR reaction (25.0 mL) contained 12.5 mL TAKARA Premix Ex
Taq (Takara Bio Inc., Shiga, Japan), primers (300 nM),
fluorescence-labeled detection probes (100 nMe300 nM;
TaqMan probe), 1.0 mL purified DNA and deionized distilled
water up to 25.0 mL. The PCR reactions for 23 target genes
were multiplexed in 16 reactions and amplified using in a
single assay using the SmartCycler II (Cepheid, Sunnyvale,
CA). The PCR was performed by starting at 95 C for 30 s
followed by 40 cycles of 95 C for 8 s, 61 C for 25 s, and
72 C for 20 s.
Statistical analysis
The 95% confidence interval (CI) was calculated using
the formula for the binomial probabilities by the
software Mathematica Ver.8 (Wolfram Research, IL,
USA) [13].
Ethical consideration
The research protocol for the current study was approved
by the institutional review boards of the Saitama Medical
University Hospital, Saitama Medical UniversityFigure 1 Determination ofDCtpathogen cutoff. The DCtpathogen was
past clinical study (n Z 533; from May 2007 to January 2009). Sam
pathogen was identified using criteria (1)e(3) (see Materials and M
line) was defined as the smallest DCtpathogen for the blue circles. T
becomes large on the Y-axis. The theoretical concept for the cuto
cutoff was defined below: (A) 1 for H. influenzae; (B) 4 for P. aer
7 for E. coli; (F) 8 for MRSA and (G) 6 for S. pneumoniae. (For in
reader is referred to the web version of this article.)International Medical Center, Kan-etsu Hospital, Saitama
Social Insurance Hospital, Tsurugashima Ikenodai Hospi-
tal, Kesennuma City Hospital and Ohno clinic (Table 2).
Observatory study registration
The prospective observatory study described in the current
report had been registered to the University Hospital
Medical Information Network (UMIN) registry before its
initiation, where the UMIN is a registry approved by the
International Committee of Medical Journal Editors
(ICMJE). The UMIN registry number was UMIN000001694: A
multicenter prospective study for the investigation of the
validity of the cutoff values established for the HIRA-TAN
system (February 06, 2009).
Results
Determination of the DCtpathogen cutoff
We confirmed that the primers and probes were specific to
7 representative commensal organisms (S. pneumoniae, H.
influenzae, Moraxella catarrhalis (M. catarrhalis), P. aer-
uginosa, Klebsiella pneumoniae (K. pneumoniae), Escher-
ichia coli (E. coli), and Methicillin-resistant Staphylococcus
aureus (MRSA)) and the human genome, and were able to
quantify their cell numbers by counting the copy numbers
(Ct value) for each in sputum. The pathogen to human cell
number ratio was described as the DCtpathogen value
[(CtpathogenCthuman)] using 533 sputum samples collected
in the past clinical study between May 2007 to January
2009. Using the microbiological examination as a reference
(see Materials and Methods), we determined the smallestmeasured for 7 representative commensal organisms from the
ples from patients with pneumonia in which a likely causative
ethods) are shown as blue circles. The DCtpathogen cutoff (a red
he pathogen to human cell ratio grows wider as the DCtpathogen
ff value was described in greater detail in [3]. The DCtpathogen
uginosa; (C) 6 for K. pneumoniae; (D) 0 for M. catarrhalis; (E)
terpretation of the references to color in this figure legend, the
Table 3 Patients’ characteristics in the prospective study
(n Z 568).
Age (year)
Mean (minemax) 67.24 (19e106)
Sex
400 T. Hirama et al.DCtpathogen value to be the DCtpathogen cutoff to discrimi-
nate the therapeutic target: 1 in the DCtH. influenzae cut-
off; 4 in the DCtP. aeruginosa cutoff; 6 in the DCtK.
pneumoniae cutoff; 0 in the DCtM.catarrhalis cutoff; 7 in the
DCtE. coli cutoff; 8 in the DCtMRSA cutoff and 6 in the
DCtS.pneumoniae cutoff, respectively (Fig. 1).Male (%) 365 (64.3%)
Female (%) 203 (35.7%)
Quality of sputums
Miller and Jones’classification
M2 (%) 134 (23.6%)
P1 (%) 130 (22.9%)
P2 (%) 95 (16.7%)
P3 (%) 209 (36.8%)
CtHomo Sapiens
Mean (minemax) 23.87
(12.78e26.99)
Type of pneumoniae
Community-acquired
pneumonia (CAP) (%)
349 (61.4%)
Healthcare-assicuated
pneumonia (HCAP) (%)
147 (25.9%)
Hospital-acquired
pneumoniae (HAP) (%)
72 (12.7%)
Time between the development of respiratory symptoms
and establishment of the diagnosis
of pneumonia
<6 h 17 (3.0%)
6e12 h 29 (5.1%)
12e24 h 131 (23.1%)
24e48 h 61 (10.7%)
48e72 h 57 (10.0%)
72 he7days 222 (39.1%)
>7days 42 (7.4%)
Unknown 9 (1.6%)
Serum CRP (mg/dl) at the time of diagnosis
Mean (minemax) 11.5 (0.1e53.0)
Radiological feature
Monolobar infiltrate 200 (35.2%)
Multilobar infiltrates 368 (64.8%)
Underlying disorder
Neoplastic disease 26 (4.6%)
Congestive heart failure 78 (13.7%)
Cerebrovascular disease 57 (10.0%)
Renal disease 39 (6.9%)
Liver disease 11 (1.9%)
Chronic Respiratory disease 132 (23.2%)
Lung cancer 51 (9.0%)
Collagen vascular disease 22 (3.9%)
Steroid usage 22 (3.9%)
Diabetes 76 (13.4%)
Psychiatric disorder (including sezure) 38 (6.7%)Prospective study
We designed a prospective study to investigate the val-
idity of the new cutoff values for the commensal organ-
isms in the HIRA-TAN system (Table 2: UMIN000001694).
The primary endpoint of the study was the proportion of
samples in which DCtH. influenzae or DCtP. aeruginosa were
greater than the cutoff value, compared to the proportion
of the samples in which H. influenzae or P. aeruginosa
were shown to be the likely causative pathogen. Thus the
endpoint was to investigate DCtH. influenzae cutoff or DCtP.
aeruginosa cutoff to classify H. influenzae or P. aeruginosa,
each identified for the likely causative pathogen as the
therapeutic target. The secondary endpoints were the
proportion for the other commensal organisms and the
proportion of the samples in which the HIRA-TAN could
identify the therapeutic targets.
The study was performed between February 06, 2009
to October 14, 2010. 568 patients were enrolled and pa-
tients’ characteristics were shown in Table 3. The results
of the microbiological examinations were summarized in
Fig. 2. The identification rates for H. influenzae and P.
aeruginosa by the HIRA-TAN were 96.7% (29/30; 95% CI
82.8e99.2%) and 93.2% (41/44; 95% CI 81.3e97.5%)
respectively (Fig. 3(A), (B)). The response of the antibi-
otics and the relief of pneumonia for the cases in which H.
influenzae or P. aeruginosa were the likely causative
pathogens showed a consistent clinical course as pre-
dicted from the result of the HIRA-TAN. The identification
rates for K. pneumoniae, M. catarrhalis, E. coli, MRSA and
S. pneumoniae were as follows 80.6% (29/36; 95% CI
64.0e89.9%), 90.9% (10/11; 95% CI 58.7e97.7%), 87.5%
(14/16; 95% CI 61.6e96.0%), 78.1% (25/32; 95% CI
60.0e88.5%) and 80.6% (87/108; 95% CI 71.8e86.8%)
(Fig. 3(C)e(G)).
Among 108 patients in which S. pneumoniae was the
likely causative pathogen (Blue circles in Fig. 3(G)-1), 39
patients were diagnosed by the positive UA test solely
(enclosed Green and Orange circles in dashed rectangle in
Fig. 3(G)-2, which were a subpopulation of the S. pneu-
moniae pneumonia diagnosed by UA test solely). Out of
these, 13 patients (Orange circles in Fig. 3(G)-2) showed
no positive blood cultures and no suggestive gram-
positive diplococci on the Gram stain, no positive cul-
ture result and no detection by PCR for the S. pneumo-
niae in the purulent sputum (MJ classification M2 to P3
and Cthuman of <27). This raises the possibility that in
these cases the UA test was a false positive. Removing
these potential false positives from our analysis results in
an increase in the positive identifications for S. pneu-
monia to a rate of 91.6% (87/95; 95% CI 84.1e95.6% in
Fig. 3(G)-2).
Currently the ability of the HIRA-TAN system to
determine if MRSA is the causative pathogen is lacking.This is due largely to the fact that for the determination
and establishment of the cutoff value for a given micro-
organism in the HIRA-TAN system still requires the con-
ventional sputum examination. To date we have not been
able to determine the DCtMRSA cutoff and this will take
more time and the availability of properly analyzed clin-
ical samples to be established.
Identification of causative agents of pneumonia 401Overall performance of HIRA-TAN system to identify
both the therapeutic target (commensal organisms judged
by the DCt cutoff) and the causative pathogen (foreign
organisms detected by the real-time PCR) was altogether
60% en masse (Fig. 4). The HIRA-TAN analysis was able to
identify the therapeutic target in 60e70% of the samples
(Fig. 4 or in the previous study [3]), which is comparable
to what is attained by an extensive search using multiple
detection methods [4,8,14].Discussion
The most prominent feature of the HIRA-TAN is its ability
to identify the causative pathogen for the pneumonias
from among the commensal organisms detected in the
sputum. Clinically, without this ability, this system would
have been only partially useful, since more than half of
pneumonias are caused by commensal organisms (Figs. 2
and 4). And this system does not require the use of
pathogen-by-pathogen identification methods. The easily
performed comprehensive test covers a wide variety of
pathogens in a single assay, which will reduce the time
and labor spent on cumbersome procedures. The HIRA-
TAN procedure now provides a comprehensive detection
system for causative pathogens of pneumonia.
The HIRA-TAN system can also be expanded to include
more pathogens and thereby increasing its abilities. The
addition of any respiratory viruses to the screeningFigure 2 Etiology of pneumonia enrolled in the prospective study
causativepathogen(s) (forthecommensalorganismsshown inorange)o
*1Mixed infection stands for the cases inwhich two ormorepathogens
pathogens at one time. (For interpretation of the references to color in
article.)protocol is straightforward [4,5,15e18]. Likewise, the
inclusion of commensal organisms, such as Acinetobacter
baumannii or Stenotrophomonas maltophilia, will also
be beneficial in the nosocomial pneumonia. Thus, the
commensal organisms that have conformed to the
scheme shown in Fig. 1 and all non-commensal organisms
become candidates, which will make the greater detec-
tion rate by the HIRA-TAN than current 60e70% per-
tnqh_0009;formance.
S. aureus is frequently isolated commensal organism
from respiratory samples, while is very often detected
the long-term hospitalized patients. Thus it is difficult to
establish a direct and causative role for this bacterium in
pneumonia. Anaerobes as well, which are important
commensal organisms for aspiration pneumonia or lung
abscess, are also lacking the standard to be determined
as causative pathogen. Since the cutoff value for
commensal organisms in the HIRA-TAN system is based on
the microbiological examination, is still incapable of
being set up for the organisms which have not yet built
the consensus for diagnosis. This should be addressed in
future iterations of the HIRA-TAN procedure.
In conclusion, the HIRA-TAN approach yielded repro-
ducible results and provided valuable information for
planning the course of treatment of pneumonia. The cur-
rent study established and validated the HIRA-TAN system.
Through the rapid identification of the causative patho-
gens, the HIRA-TAN will promote targeted treatments for
pneumonias.by conventional method. Description of isolates either a likely
racausativepathogen(s) (for theforeignorganismsshowningreen)
were isolated among either likely causative pathogens or causative
this figure legend, the reader is referred to theweb version of this
Figure 3 DCtpathogen for each commensal organisms in the prospective study (nZ 568). Samples from patients with pneumonia in
which a likely causative pathogen was identified using criteria (1)e(3) (see Materials and Methods) are shown as blue circles, and
samples from patients with pneumonia in which none of criteria (1)e(3) was fulfilled were shown as white circles. The 30th case in
which H. influenzae was a likely causative pathogen was enrolled on October 14, 2010, which terminated the prospective study.
The HIRA-TAN identified the likely causative pathogens; (A) 96.7% for H. influenzae; (B) 93.2% for P. aeruginosa; (C) 80.6% for K.
pneumoniae; (D) 90.9% for M. catarrhalis; (E) 87.5% for E. coli; (F) 78.1% for MRSA and (G) 91.6% for S. pneumoniae. The Blue circles
in G-1 and G-2 showed the samples which S. pneumoniae was identified by blood cultures, sputum smears and cultures and/or UA
test. Green and Orange circles in G-2, which were enclosed in dashed rectangle, were created subpopulation of the samples which
S. pneumoniae was identified by UA test solely. Orange circles indicated no positive blood cultures, no suggestive gram-positive
diplococcic on the Gram stain, no positive sputum culture and no detection by PCR for S. pneumoniae in the purulent sputum.
The bottom two blue circles in F and the bottom 14 blue circles in G-1 were the likely causative pathogen for MRSA and S.
pneumoniae, respectively, but not identified by real-time PCR. (For interpretation of the references to color in this figure legend,
the reader is referred to the web version of this article.)
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Figure 4 Etiologyofpneumoniaenrolled in theprospective studyby theHIRA-TANsystem.Descriptionof isolateseither a therapeutic
target(s) (for the commensal organisms shown in orange) or a causative pathogen(s) (for the foreign organisms shown in green) *1 Mixed
infection stands for the case in which two ormore pathogens were isolated among either therapeutic targets or causative pathogens at
one time. (For interpretation of the references to color in this figure legend, the reader is referred to the web version of this article.)
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